Landscape Corten Steel Garden Edging Landscape garden edging is a steel lawn edging which can securely anchor into the ground providing alean and even edge to your paths and flower beds. It's strong and looks very attractive.The main material for garden edging is corten steel can develop a rusty looking protective patina that looks very natural.Galvanized steel wiowder coating Is very beautifulle normal thickness is 2mm. The steel garden edging can be made flexible to allow virtually any shape to be easily formed.Edging your garden beds is an essential step that many people skip, which leads to a garden that looks unfinished and bare. Your plants might be blooming beautifully, but if the bed they are in looks unkept, it can ruin the entire look. Edging your garden takes a little extra dirty work, but it's worth it in the end. There are a variety of edging materials you can choose that range in price, installation difficulty, and durability. Here are a few of our go-tos.   Steel Garden Edging,Corten Edging,Garden Edging,Steel Garden Edging Henan Jinbailai Industrial Co.,Ltd , https://www.gardensteelarts.com
Name
Landscape Corten Steel Garden Edging
Material
Corten steel
Size
1000mm long,2mm thick,200mm high or customized
Steel thickness
2mm
Packing
Pallet/carton/wooden box packing
New combination therapy for effective treatment of ALS
November 28, 2014 / Bio Valley BIOON / — Amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that leads to the loss of motor neurons, resulting in muscle atrophy, paralysis, and ultimately death. Currently, there is no known cure for ALS, and many experimental drugs have failed during clinical trials.
In a recent study published in the journal *Annals of Clinical and Translational Neurology* on November 20, researchers discovered that the brain's ability to expel toxins is heightened in ALS patients. This same mechanism also removes therapeutic drugs used to treat ALS, which can significantly reduce their effectiveness. The findings suggest that when these toxin-pumping systems are inhibited, ALS medications become more potent, leading to slower disease progression in mouse models.
This pumping mechanism, typically responsible for protecting the brain and spinal cord from harmful substances, also clears out medication, which may explain why some treatments fail to work as expected. By blocking these transporters, scientists believe they can enhance drug efficacy and improve outcomes for ALS patients.
Earlier research by the same team showed that these pumps become more active as the disease advances, especially when symptoms worsen. To tackle this challenge, the researchers tested a combination of riluzole—a drug approved for ALS treatment—and elacridar, a pump blocker, in an ALS mouse model.
Riluzole has been shown to extend survival in ALS patients by only 3 to 6 months, and its effectiveness often diminishes as the disease progresses. The team selected riluzole for their experiments because it interacts with two key drug transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
When mice were treated with both riluzole and elacridar, they experienced longer survival times compared to those receiving riluzole alone. These results highlight the potential of combining ALS drugs with pump inhibitors to overcome drug resistance and improve treatment outcomes.
This breakthrough offers hope for future therapies and underscores the importance of targeting the brain’s natural detoxification systems in the fight against ALS. (Bio Valley Bioon.com)